News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sunovion Pharmaceuticals Inc. (SEPR) Release: Latuda(R) (lurasidone HCl) was Associated with Low Rates of Weight Gain and Metabolic Changes in Patients with Schizophrenia in Data Presented at the 164th Meeting of the American Psychiatric Association



5/18/2011 10:02:42 AM

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. today announced results from a new pooled data analysis on weight and metabolic parameters across short- and long-term studies in adult patients with schizophrenia treated with Latuda® (lurasidone HCl) tablets. These data were presented at the Annual Meeting of the American Psychiatric Association in Honolulu, Hawaii.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES